These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24357849)

  • 1. Large numbers of individuals are required to classify and define risk for rare variants in known cancer risk genes.
    Shirts BH; Jacobson A; Jarvik GP; Browning BL
    Genet Med; 2014 Jul; 16(7):529-34. PubMed ID: 24357849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Power of pedigree likelihood analysis in extended pedigrees to classify rare variants of uncertain significance in cancer risk genes.
    Rosenthal EA; Ranola JMO; Shirts BH
    Fam Cancer; 2017 Oct; 16(4):611-620. PubMed ID: 28534081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating causal effects of genetic risk variants for breast cancer using marker data from bilateral and familial cases.
    Dudbridge F; Fletcher O; Walker K; Johnson N; Orr N; Dos Santos Silva I; Peto J
    Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):262-72. PubMed ID: 22028405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
    Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
    Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
    Li N; Rowley SM; Thompson ER; McInerny S; Devereux L; Amarasinghe KC; Zethoven M; Lupat R; Goode D; Li J; Trainer AH; Gorringe KL; James PA; Campbell IG
    Breast Cancer Res; 2018 Jan; 20(1):3. PubMed ID: 29316957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare
    Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
    Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing.
    Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Holth A; Capella G; Davidson B; Evans DG; Martins A; Møller P; Hovig E
    Sci Rep; 2019 Dec; 9(1):18555. PubMed ID: 31811167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imputation-based assessment of next generation rare exome variant arrays.
    Martin AR; Tse G; Bustamante CD; Kenny EE
    Pac Symp Biocomput; 2014; ():241-52. PubMed ID: 24297551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
    van Marcke C; Collard A; Vikkula M; Duhoux FP
    Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations and germline sequence variants in patients with familial colorectal cancer.
    Gylfe AE; Sirkiä J; Ahlsten M; Järvinen H; Mecklin JP; Karhu A; Aaltonen LA
    Int J Cancer; 2010 Dec; 127(12):2974-80. PubMed ID: 21351276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of ATM missense variants and mutations in a series of unselected breast cancer cases.
    Rodriguez C; Vallès H; Causse A; Johannsdottir V; Eliaou JF; Theillet C
    Genes Chromosomes Cancer; 2002 Feb; 33(2):141-9. PubMed ID: 11793440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A powerful association test of multiple genetic variants using a random-effects model.
    Cheng KF; Lee JY; Zheng W; Li C
    Stat Med; 2014 May; 33(11):1816-27. PubMed ID: 24338936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
    Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
    Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
    Sepahi I; Faust U; Sturm M; Bosse K; Kehrer M; Heinrich T; Grundman-Hauser K; Bauer P; Ossowski S; Susak H; Varon R; Schröck E; Niederacher D; Auber B; Sutter C; Arnold N; Hahnen E; Dworniczak B; Wang-Gorke S; Gehrig A; Weber BHF; Engel C; Lemke JR; Hartkopf A; Nguyen HP; Riess O; Schroeder C
    BMC Cancer; 2019 Aug; 19(1):787. PubMed ID: 31395037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.
    Melloni GEM; Mazzarella L; Bernard L; Bodini M; Russo A; Luzi L; Pelicci PG; Riva L
    Breast Cancer Res; 2017 May; 19(1):63. PubMed ID: 28569218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of genome sequencing in personalized breast cancer prevention.
    Sieh W; Rothstein JH; McGuire V; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2322-7. PubMed ID: 25342391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
    Osorio A; Milne RL; Honrado E; Barroso A; Diez O; Salazar R; de la Hoya M; Vega A; Benítez J
    Hum Mutat; 2007 May; 28(5):477-85. PubMed ID: 17279547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.